UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture

To ensure safe, high-quality Advanced Therapy Medicinal Products (ATMPs) are delivered to patients, procurement activities must be standardized when possible. Standardization also supports efficiency and reduces the risk for error while meeting regulatory and accreditation requirements. Download the UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture for insights…

The EBMT/EHA CAR-T Cell Handbook

A joint venture between the European Society of Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), the CAR-T Cell Handbook offers clinical care applications for health care professionals in the EU that treat patients with CAR-T cell therapies. Download the guide for insights into many aspects of CAR-T cell therapies including: The…

6 Considerations When Evaluating Cell Sourcing Partners

Sourcing your starting material from healthy, high-quality donors matters when you are manufacturing an allogeneic cell therapy. Any misstep can mean delays in your therapy’s development. Keep these key considerations top of mind as you evaluate whether potential partners have the experience, expertise and relationships required to identify, source and collect your allogeneic donors and…

How to Overcome 3 Common Cell Therapy Supply Chain Disruptions

The successful on-time delivery of cell and gene therapies isn’t just good business—it’s a matter of survival for patients. When there’s no room for mistakes, you need an advanced approach to overcome barriers to on-time delivery. In our more than 30 years of experience managing the collection and delivery for time-sensitive cell therapies around the…

5 Considerations to Lower Your Risk When Selecting a Supply Chain Partner

As your therapy operations scale from early-phase clinical trials to larger populations in late-stage trials and commercialization, your supply chain complexity—and risk—increases. Anticipating common setbacks and actively planning for their solution requires a specialized and collaborative approach with your supply chain logistics partner. Keep these key considerations top of mind as you evaluate whether potential…

Streamlining Your Supply Chain to Support Next-Gen Therapies

As your cell and gene therapies move from early-phase clinical trials to commercialization, your supply chain complexity—and risk—increases. Anticipating setbacks and planning for their solution requires a specialized and collaborative approach with your supply chain partner. During this on-demand webinar, you’ll hear from industry experts who offer insights into developing a commercial supply chain for emerging autologous and allogeneic…

Scaling Up and Out: Developing a Commercial Supply Chain Strategy to Successfully Deliver Next-Generation Therapies

With the introduction of innovative cell and gene therapies to market, scalable commercial strategies are critical to successfully delivering these therapies to patients. The delivery of cell and gene therapies depends on well-designed supply chains. Scaling your supply chain up to achieve this requires having, or finding partners with, proven experience in navigating supply chain…

From Clinic to Commercial Reality: Leveraging Transplant Experience to Overcome Cell Therapy Supply Chain Hurdles

View this on-demand presentation by our Director of Cell and Gene Therapy Operations, Jamie Margolis, PhD, and our Vice President of Business Development and Strategic Partnerships, Mark Flower, to learn more about how Be The Match BioTherapies® is going beyond hematopoietic cell transplant and leveraging 30+ years of experience in managing stem cell transplants to…